Dissecting the Bladder Tumour Microenvironment with MB49 21st January 2026

Dissecting the Bladder Tumour Microenvironment with MB49 21st January 2026 Cell lines Introduction Immunotherapy has started to transform bladder cancer treatment, but durable responses remain the exception rather than the rule. Understanding why requires models that capture the tumour microenvironment, not just tumour growth. This blog explores how the MB49 syngeneic bladder cancer model – across subcutaneous, orthotopic, MB49-luc, and metastatic formats – dissects myeloid-dominated “cold” TMEs, neutrophil-driven immune escape, BCG response, and PD-L1-dependent checkpoint timing. https://cancertools.org/dissecting-bladder-tumour-microenvironment-with-mb49/?utm_term=3rd%20party%20-%20DDN%20-%20MB49%20blog&utm_campaign=43046019-Bladdercancer_DM_BrandAwareness_ALL_2026&utm_medium=3rd%20party%20-%20DDN%20-%20MB49%20blog&_hsenc=p2ANqtz--FJN0fijn2qnnW93DyMevFIKuE7zjKxplXeN_tIUh52Ae7k9kLYqHh46kHvpVUZFt95kA8wDpij8WmRUYr3TubgDVI_g&_hsmi=416164333&utm_content=3rd%20party%20-%20DDN%20-%20MB49%20blog&utm_source=3rd%20party%20-%20DDN%20-%20MB49%20blog